529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors by Rebecca Kristeleit, Howard Burris, Kristen Spencer, Sarina Piha-Paul, Hans Prenen, Tara Mitchell, David Pinato, Solmaz Sahebjam, Donna Graham, Nuria Kotecki, Eric Van Cutsem, Brant Delafontaine, Thomas Karasic, Jeannie Daniel, Kevin O’Hayer, Ryan Geschwindt

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study by Michael Smith, Ignacio Garrido-Laguna, Aung Naing, Lance Leopold, Jason J Luke, Kai Ding, Solmaz Sahebjam, Ryan Geschwindt, John D Powderly, John J Nemunaitis, Aaron S Mansfield, Wells A Messersmith, Patricia M LoRusso, Jordan D Berlin

Get full text